SPX3,783.28-7.65 -0.20%
DIA302.79-0.35 -0.12%
IXIC11,148.64-27.77 -0.25%

BRIEF-Revive Therapeutics Announces Submission Of Amended Phase 3 Covid-19 Study Protocol To FDA

BRIEF-Revive Therapeutics Announces Submission Of Amended Phase 3 Covid-19 Study Protocol To FDA

Reuters · 09/14/2022 06:01
BRIEF-Revive Therapeutics Announces Submission Of Amended Phase 3 Covid-19 Study Protocol To FDA

- Revive Therapeutics Ltd RVV.CD:

  • REVIVE THERAPEUTICS ANNOUNCES SUBMISSION OF AMENDED PHASE 3 COVID-19 STUDY PROTOCOL TO FDA

  • REVIVE THERAPEUTICS LTD - NOW SUBMITTED TO FDA A REVISED PROTOCOL FOR FURTHER DISCUSSION AND AGREEMENT ADDRESSING A NEW PRIMARY EFFICACY ENDPOINT

  • REVIVE THERAPEUTICS LTD - PROPOSED ENDPOINTS ADDRESS SHIFT IN COVID-19 CLINICAL OUTCOMES OBSERVED OVER COURSE OF PANDEMIC

Source text for Eikon: ID:

Further company coverage: RVV.CD


((Reuters.Briefs@thomsonreuters.com;))